The United States has revealed price reductions for the second round of | The U.S. has revealed price reductions for the ...
More than 30 agents conducted a surprise raid of Sanofi’s headquarters in Paris on Tuesday morning as part of a tax fraud ...
Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...
Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add ...
AstraZeneca’s Imfinzi is adding yet another landmark perioperative label to its belt with a new FDA approval that gives the ...
Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National ...
A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to ...
The U.K. drug marketing watchdog has ruled that a presentation calling the European Medicines Agency (EMA) “stupid” brought ...
With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...
A new FDA approval for a first-in-class drug has vaulted Otsuka into immunoglobulin A nephropathy (IgAN), an increasingly competitive kidney disease field targeted by multiple biopharma companies.
Anti-vaccine sentiment is alive and well, especially in the U.S. And it was evident in recent weeks as drugmakers revealed ...
A recent survey has found that pharma marketing and promotional review professionals are skeptical of the outputs of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results